These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27908680)

  • 1. The effect of contralateral kidney volume on renal function after radical nephroureterectomy: Implications for eligibility for neoadjuvant chemotherapy for upper tract urothelial cancer.
    Song W; Sung HH; Han DH; Jeong BC; Seo SI; Jeon SS; Lee HM; Choi HY; Jeon HG
    Urol Oncol; 2017 Mar; 35(3):114.e1-114.e7. PubMed ID: 27908680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.
    Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF
    Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
    Xylinas E; Rink M; Margulis V; Clozel T; Lee RK; Comploj E; Novara G; Raman JD; Lotan Y; Weizer A; Roupret M; Pycha A; Scherr DS; Seitz C; Ficarra V; Trinh QD; Karakiewicz PI; Montorsi F; Zerbib M; Shariat SF;
    BJU Int; 2013 Aug; 112(4):453-61. PubMed ID: 23464979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and oncologic impact of chronic kidney disease for upper tract urothelial carcinoma in endemic area.
    Lee IW; Wang HJ; Liu HY; Chang YL; Wu YT; Chen YT; Cheng YT; Kang CH; Chuang YC; Luo HL
    J Formos Med Assoc; 2024 Jul; 123(7):758-763. PubMed ID: 38044211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma.
    Singla N; Hutchinson R; Haddad A; Sagalowsky A; Lotan Y; Margulis V
    Can J Urol; 2016 Aug; 23(4):8334-41. PubMed ID: 27544555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract.
    Cho KS; Joung JY; Seo HK; Cho IC; Chung HS; Chung J; Lee KH
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):769-74. PubMed ID: 20532510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for impaired renal function following nephroureterectomy in upper urinary tract urothelial cell carcinoma.
    Rodríguez Faba O; Palou J; Breda A; Maroto P; Fernández Gómez JM; Wong A; Villavicencio H
    Urol Int; 2014; 92(2):169-73. PubMed ID: 24280761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.
    Dudinec JV; Ortiz-Melo DI; Lipkin ME; Abern MR; Shah AM; Inman BA
    Urol Oncol; 2023 Jun; 41(6):295.e19-295.e25. PubMed ID: 36526526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.
    Tabayoyong W; Li R; Gao J; Kamat A
    Urol Clin North Am; 2018 May; 45(2):155-167. PubMed ID: 29650132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy.
    Fletcher SA; Pallauf M; Watts EK; Lombardo KA; Campbell JA; Rezaee ME; Rouprêt M; Boorjian SA; Potretzke AM; Roshandel MR; Ploussard G; Djaladat H; Ghoreifi A; Mari A; Campi R; Khene ZE; Raman JD; Kikuchi E; Rink M; Abdollah F; Boormans JL; Fujita K; D'Andrea D; Soria F; Breda A; Hoffman-Censits J; McConkey DJ; Shariat SF; Pradere B; Singla N
    Eur Urol Oncol; 2024 Oct; 7(5):1061-1068. PubMed ID: 38262800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A role for preoperative systemic chemotherapy in node-positive upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Kitamura H; Igarashi M; Tanaka T; Shindo T; Masumori N; Tamakawa M; Kawaai Y; Tsukamoto T
    Jpn J Clin Oncol; 2012 Dec; 42(12):1192-6. PubMed ID: 23077244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy.
    Shao IH; Lin YH; Hou CP; Juang HH; Chen CL; Chang PL; Tsui KH
    Drug Des Devel Ther; 2014; 8():1985-90. PubMed ID: 25364228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.
    Kaag M; Trost L; Thompson RH; Favaretto R; Elliott V; Shariat SF; Maschino A; Vertosick E; Raman JD; Dalbagni G
    BJU Int; 2014 Nov; 114(5):674-9. PubMed ID: 24314050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
    Liao RS; Gupta M; Schwen ZR; Patel HD; Kates M; Johnson MH; Hahn NM; McConkey D; Bivalacqua TJ; Pierorazio PM
    J Urol; 2018 Jul; 200(1):68-73. PubMed ID: 29307680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of renal function after nephroureterectomy in patients with upper tract urothelial carcinoma.
    Hashimoto T; Ohno Y; Nakashima J; Gondo T; Nakagami Y; Namiki K; Horiguchi Y; Yoshioka K; Ohori M; Tachibana M
    Jpn J Clin Oncol; 2015 Nov; 45(11):1064-8. PubMed ID: 26355160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma.
    Singla N; Gayed BA; Bagrodia A; Krabbe LM; Palazzi KL; Mirheydar H; Harrow B; Jacobs C; Youssef R; Darwish O; Sagalowsky A; Lotan Y; Derweesh I; Margulis V
    Urol Oncol; 2015 Jun; 33(6):268.e1-7. PubMed ID: 25862284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
    Lu DD; Boorjian SA; Raman JD
    Urol Oncol; 2017 Mar; 35(3):113.e1-113.e7. PubMed ID: 27884539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy.
    Lane BR; Smith AK; Larson BT; Gong MC; Campbell SC; Raghavan D; Dreicer R; Hansel DE; Stephenson AJ
    Cancer; 2010 Jun; 116(12):2967-73. PubMed ID: 20564402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis.
    Yuan H; Chen X; Liu L; Yang L; Pu C; Li J; Bai Y; Han P; Wei Q
    Urol Oncol; 2014 Oct; 32(7):989-1002. PubMed ID: 25082191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients.
    Thompson RH; Boorjian SA; Kim SP; Cheville JC; Thapa P; Tarrel R; Dronca R; Costello B; Frank I
    BJU Int; 2014 May; 113(5b):E17-21. PubMed ID: 24006893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.